RxDoctor Payments Data

Harsh Chawla, MD

Internal Medicine · Williamston, NCNPI 1003070350

Payments from drug & device makers

$4,735in general payments, 2019–2025

Across 181 payments — averaging $26.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$1K
  • AstraZeneca$1K
  • GSK$718
  • Boehringer Ingelheim$323
  • Advanced Respiratory, Inc$167
  • Sanofi$112
  • plus $711 from 16 others

What the payments were for

  • Consulting fees$160%
  • Travel & lodging$1,37329%
  • Food & beverage$3,19768%
  • Education$1503%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,735 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$77,490
Medicare patients
250
Services billed
1,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter422$295,228
Breztri AerosphereBudesonide/Glycopyr/Formoterol83$62,559
Spiriva RespimatTiotropium Bromide71$44,144
DuleraMometasone/Formoterol52$20,791
EliquisApixaban28$18,152
Stiolto RespimatTiotropium Br/Olodaterol Hcl28$13,393
SymbicortBudesonide/Formoterol Fumarate34$8,344
Fluticasone-SalmeterolFluticasone Propion/Salmeterol44$5,852
Incruse ElliptaUmeclidinium Bromide14$5,837
Albuterol Sulfate HfaAlbuterol Sulfate154$4,236
Fluticasone Propionate219$3,040
Azelastine Hcl108$3,009
Roflumilast52$2,881
Montelukast Sodium528$2,854
Mycophenolate Mofetil57$2,770

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Incruse Ellipta, Arnuity Ellipta$718$303,684447 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,330$70,904117 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$323$57,53799 claims
MerckDulera$84$20,79152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Williamston

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →